WO2015071889A1 - Compositions orales de saxagliptine - Google Patents

Compositions orales de saxagliptine Download PDF

Info

Publication number
WO2015071889A1
WO2015071889A1 PCT/IB2014/066137 IB2014066137W WO2015071889A1 WO 2015071889 A1 WO2015071889 A1 WO 2015071889A1 IB 2014066137 W IB2014066137 W IB 2014066137W WO 2015071889 A1 WO2015071889 A1 WO 2015071889A1
Authority
WO
WIPO (PCT)
Prior art keywords
coating
tablets
polymer
core
layer
Prior art date
Application number
PCT/IB2014/066137
Other languages
English (en)
Inventor
Ravindra Agarwal
Puneet Kumar Gupta
Ravi Kochhar
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of WO2015071889A1 publication Critical patent/WO2015071889A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Definitions

  • the present invention relates to oral pharmaceutical compositions comprising saxagliptin and processes for their preparation. It further relates to oral pharmaceutical compositions comprising saxagliptin in combination with other antidiabetic agents.
  • Saxagliptin is a dipeptidyl peptidase IV (DPP-IV) inhibitor used for the treatment of type 2 diabetes mellitus.
  • DPP-IV dipeptidyl peptidase IV
  • U.S. Patent No. 6,395,767 discloses the compound saxagliptin.
  • DPP-IV is an enzyme that catalyses the conversion of glucagon-like peptide- 1
  • GLP-1 from its active form to its inactive form.
  • Saxagliptin competitively inhibits the DPP-IV enzyme, thereby increasing the endogenous concentration of GLP-1, which further augments insulin secretion and improves the glycemic profile of patients with type 2 diabetes mellitus.
  • U.S. Patent No. 7,951,400 describes saxagliptin as an unstable compound which easily undergoes intramolecular cyclization to form a cyclic amidine, which is not desirable for therapeutic activity. This process of cyclization is accelerated by the use of common processes of formulation, e.g., granulation or compaction. In order to provide a stable formulation wherein saxagliptin is less prone to cyclization, U.S. Patent No.
  • 7,951,400 provides a coated tablet formulation of saxagliptin containing a polyvinyl alcohol based coating.
  • the present invention provides alternative oral pharmaceutical compositions comprising saxagliptin.
  • the present invention provides oral pharmaceutical compositions comprising saxagliptin and processes for their preparation.
  • the oral pharmaceutical compositions are preferably in the form of coated tablets comprising a core and a coating layer surrounding the core, wherein the drug is present in said coating.
  • the present invention also relates to oral pharmaceutical compositions comprising saxagliptin in combination with other antidiabetic agents. Detailed Description of the Invention
  • a first aspect of the present invention provides an oral pharmaceutical composition comprising saxagliptin, wherein said composition comprises:
  • a second aspect of the present invention provides an oral pharmaceutical composition comprising saxagliptin, wherein said composition comprises:
  • the polymer in any one of the layers (b), (c), or (d) is not a polyvinyl alcohol based polymer.
  • a third aspect of the present invention provides an oral pharmaceutical composition comprising saxagliptin, wherein said composition comprises:
  • each of the layers (b), (c), and (d) is not a polyvinyl alcohol based polymer.
  • saxagliptin refers to saxagliptin and its
  • salts or esters may be prepared from an inorganic acid selected from the group comprising hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, carbonic acid, bicarbonic acid, sulfuric acid, phosphoric acid, and bisulphonic acid; or an organic acid selected from the group comprising oxalic acid, formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, gluconic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, glucuronic acid, maleic acid, fumaric acid, pyruvic acid, aspartic acid, glutamic acid, benzoic acid, anthranilic acid, mesylic acid, salicyclic acid, p-hydroxybenzoic acid, phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid
  • Saxagliptin used in the composition of the present invention may be present in its crystalline form, amorphous form, anhydrous form, hydrate form, or mixtures thereof.
  • the term "core,” as used herein, refers to an inert core or a compressed tablet core optionally containing an additional antidiabetic agent other than saxagliptin.
  • the inert core may include an insoluble, swellable, or soluble core.
  • the insoluble or swellable inert core may be made of dicalcium phosphate, microcrystalline cellulose, or any of the marketed inert cores, e.g. , glass beads, silicate beads, sugar spheres, non-pareils, or celphere.
  • the soluble core may include glucose, mannitol, lactose, xylitol, dextrose, or sucrose.
  • the compressed tablet core may comprise pharmaceutically acceptable excipients selected from the group comprising binders, fillers, disintegrants, plasticizers, extended- release polymers, lubricants, glidants, or mixtures thereof, and may be prepared by the process of direct compression or granulation.
  • said core optionally contains an additional antidiabetic agent other than saxagliptin.
  • said core containing an additional antidiabetic agent other than saxagliptin is coated with an extended-release coating.
  • the seal layer optionally contains an additional antidiabetic agent other than saxagliptin.
  • the drug layer optionally contains an additional antidiabetic agent in addition to saxagliptin.
  • the outer layer optionally contains an additional antidiabetic agent other than saxagliptin.
  • composition provides an immediate-release or an extended-release of the additional antidiabetic agent.
  • the additional antidiabetic agent is selected from the group comprising acarbose, miglitol, repaglinide, nateglinide, chlorpropamide, glibenclamide, gliclazide, glimepiride, glipizide, glyclopyramide, tolazamide, tolbutamide, buformin, metformin, phenformin, rosiglitazone, pioglitazone, troglitazone, faraglitazar, englitazone, darglitazone, isaglitazone, reglitazar, rivoglitazone, liraglutide, muraglitazar, peliglitazar, tesaglitazar, sitagliptin, vildagliptin, linagliptin, dutogliptin, alogliptin, canagliflozin, dapagliflozin, remogliflozin, sergliflozin
  • the additional antidiabetic agent is metformin or pharmaceutically acceptable salts or esters thereof.
  • the additional antidiabetic agent is metformin hydrochloride.
  • the coating polymer that is not a polyvinyl alcohol based polymer is selected from the group comprising hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxymethyl cellulose, carboxymethyl cellulose, methyl cellulose, sodiumcarboxymethyl cellulose, polyvinyl pyrrolidone, polysaccharides, starch and its derivatives, gums, alginates, acrylic acid derivatives, polyethylene glycol, polyalkylene glycols, mannitol, sucrose, lactose, xylitol, and mixtures thereof.
  • coating compositions comprising film-forming polymers marketed under various trade names, such as Opadry ® and Sepifilm ® LP 010, may also be used for coating.
  • an oral pharmaceutical composition comprising saxagliptin wherein said composition is in the form of pellets or tablets.
  • the pellets may further be filled into capsules or compressed into tablets.
  • an oral pharmaceutical composition comprising saxagliptin wherein said composition further comprises pharmaceutically acceptable excipients selected from the group comprising fillers, binders, plasticizers, disintegrants, lubricants, glidants, and mixtures thereof.
  • the coating suspension optionally contains pharmaceutically acceptable excipients selected from the group comprising plasticizers, colorants, antioxidants, solvents, and mixtures thereof.
  • Suitable fillers are selected from the group comprising starch, lactose, sucrose, glucose, sorbitol, calcium carbonate, calcium phosphate dibasic, calcium phosphate tribasic, calcium sulfate, microcrystalline cellulose, silicified microcrystalline cellulose, dextrates, dextrins, dextrose, fructose, lactitol, mannitol, sorbitol, pregelatinized starch, and mixtures thereof.
  • Suitable binders are selected from the group comprising methyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinylpyrrolidone, poloxamer, gelatin, ethyl cellulose, polyvinyl alcohol, pullunan, pregelatinized starch, agar, tragacanth, sodium alginate, propylene glycol, gum arabic, and mixtures thereof.
  • Suitable plasticizers are selected from the group comprising propylene glycol, triethylene glycol, oleic acid, ethylene glycol monooleate, triethyl citrate, triacetin, diethyl phthalate, glyceryl monostearate, dibutyl sebacate, acetyl triethyl citrate, castor oil, and mixtures thereof.
  • Suitable disintegrants are selected from the group comprising cross-linked polyvinylpyrrolidone, sodium starch glycolate, cross-linked sodiumcarboxymethyl cellulose, calciumcarboxymethyl cellulose, alginic acid, alginates, pregelatinized starch, starch and its derivatives, low-substituted hydroxypropyl cellulose, and mixtures thereof.
  • Suitable lubricants and glidants are selected from the group comprising colloidal anhydrous silica, magnesium stearate, calcium stearate, stearic acid, talc, hydrogenated castor oil, sucrose esters of fatty acids, and mixtures thereof.
  • Suitable antioxidants are selected from the group comprising tocopherol, L- ascorbic acid and its sodium or calcium salts, ascorbyl palmitate, propyl gallate, octyl gallate, dodecyl gallate, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), and mixtures thereof.
  • Suitable solvents are selected from aqueous solvents or non-aqueous solvents.
  • the non-aqueous solvents are selected from the group comprising an ester such as ethyl acetate, n-butyl acetate, or n-hexyl acetate; a ketone such as methyl ethyl ketone or methyl isobutyl ketone; glycol ether; alcohols; hydrocarbons; chlorinated hydrocarbons; and mixtures thereof.
  • Suitable extended-release polymers are selected from the group comprising cellulose esters, such as cellulose acetate, cellulose diacetate, cellulose triacetate, cellulose acetate propionate, or cellulose acetate butyrate; cellulose ethers, such as
  • hydroxypropylmethyl cellulose hydroxypropyl cellulose, or ethylcellulose
  • polyvinyl acetate polyvinyl acetate
  • methacrylic acid copolymers and mixtures thereof.
  • the coloring agents of the present invention may be selected from any FDCA approved colors for oral use.
  • Coating may be carried out using a conventional coating pan, a spray coater, a rotating perforated pan, or an automated system, such as a centrifugal fluidizing granulator, a fluidized bed process, or any other suitable automated coating equipment.
  • the oral pharmaceutical composition of the present invention may be prepared by a process which comprises the steps of:
  • step (ii) optionally coating the core tablets of step (i) with a coating polymer to obtain seal-coated tablets;
  • step (iii) coating the seal-coated tablets of step (ii) with a layer comprising
  • step (iv) coating the drug -layered tablets of step (iii) with a coating polymer to form an outer layer.
  • the oral pharmaceutical composition of the present invention may be prepared by a process which comprises the steps of:
  • step (i) forming core tablets comprising excipients using direct compression; (ii) coating the core tablets of step (i) with a coating polymer to obtain seal- coated tablets;
  • step (iii) coating the seal-coated tablets of step (ii) with a layer comprising
  • step (iv) coating the drug -layered tablets of step (iii) with a coating polymer to form an outer layer wherein the polymer in any one of the layers (ii), (iii), or (iv) is not a polyvinyl alcohol based polymer.
  • the oral pharmaceutical composition of the present invention may be prepared by a process which comprises the steps of:
  • step (ii) coating the core tablets of step (i) with a coating polymer to obtain seal- coated tablets;
  • step (iii) coating the seal-coated tablets of step (ii) with a layer comprising
  • the polymer in each of the layers (ii), (iii), and (iv) is not a polyvinyl alcohol based polymer.
  • the oral pharmaceutical composition of the present invention may be prepared by a process which comprises the steps of:
  • step (ii) optionally coating the core tablets of step (i) with a coating polymer to obtain seal-coated tablets;
  • step (iii) coating the tablets of step (i) or the seal-coated tablets of step (ii) with a layer comprising saxagliptin and a coating polymer to obtain drug-layered tablets;
  • step (iv) coating the drug -layered tablets of step (iii) with a coating polymer to form an outer layer.
  • the oral pharmaceutical composition of the present invention may be prepared by a process which comprises the steps of:
  • step (i) forming core tablets comprising excipients and an additional antidiabetic agent other than saxagliptin using wet granulation; (ii) coating the core tablets of step (i) with a coating polymer to obtain seal- coated tablets;
  • step (iii) coating the seal-coated tablets of step (ii) with a layer comprising
  • step (iv) coating the drug -layered tablets of step (iii) with a coating polymer to form an outer layer
  • the polymer in any one of the layers (ii), (iii), or (iv) is not a polyvinyl alcohol based polymer.
  • the oral pharmaceutical composition of the present invention may be prepared by a process which comprises the steps of:
  • step (ii) coating the core tablets of step (i) with a coating polymer to obtain seal- coated tablets;
  • step (iii) coating the seal-coated tablets of step (ii) with a layer comprising
  • step (iv) coating the drug -layered tablets of step (iii) with a coating polymer to form an outer layer
  • the polymer in each of the layers (ii), (iii), and (iv) is not a polyvinyl alcohol based polymer.
  • the oral pharmaceutical composition of the present invention may be prepared by a process which comprises the steps of:
  • step (ii) coating the metformin pellets of step (i) with a layer comprising an
  • step (iii) coating the extended-release metformin pellets of step (ii) with a coating polymer to obtain seal-coated pellets; (iv) coating the seal-coated pellets of step (iii) with a layer comprising saxagliptin and a coating polymer to obtain saxagliptin coated pellets;
  • step (v) coating the saxagliptin coated pellets of step (iv) with a coating polymer to form an outer coating layer over the pellets;
  • step (vi) filling the pellets of step (v) into hard gelatin capsules.
  • Core Tablets i) Blend lactose monohydrate, croscarmellose sodium, and microcrystalline cellulose together in a blender.
  • step ii) Lubricate the blend of step i) with magnesium stearate.
  • step iii) Compress the lubricated blend of step iii) into core tablets.
  • step vi) Add the dispersion of step v) slowly to the solution of step vi) under stirring while maintaining the pH at 2.
  • step vii) Coat the core tablets of step iii) with the dispersion of step vi) to form a seal layer over the core.
  • step x) Combine the solution of step viii) with the solution of step ix).
  • step xii) Add the dispersion of step xi) slowly to the solution of step x) under stirring, while maintaining the pH at 2.
  • step xiii) Coat the seal coated tablets of step vii) with the drug dispersion of step xii) to obtain drug-layered tablets.
  • xiv) Dissolve hydroxypropylmethyl cellulose in 0.1 N hydrochloric acid to obtain a clear solution.
  • xv) Coat the drug-layered tablets of step xiii) with the dispersion of step obtain an outer coating layer over the tablets.
  • Lactose monohydrate, croscarmellose sodium, and microcrystalline cellulose were blended together.
  • step i) The blend of step i) was lubricated with magnesium stearate.
  • step iii) The lubricated blend of step ii) was compressed into core tablets.
  • step iv) Hydroxypropylmethyl cellulose was dissolved in 0.1 N hydrochloric acid to obtain a clear solution.
  • the core tablets of step iii) were coated with the dispersion of step iv) to form seal-coated tablets.
  • step vi) was combined with the solution of step vii).
  • step x) The dispersion of step ix) was added slowly to the solution of step viii) under stirring, while maintaining the pH at 2.
  • step v) The seal-coated tablets of step v) were coated with the drug dispersion of step x) to obtain drug -layered tablets.
  • step xiv) The dispersion of step xiii) was added slowly to the solution of step xii) under stirring, while maintaining the pH at 2.
  • step xi) The drug-layered tablets of step xi) were coated with the dispersion of step xiv) to obtain an outer coating layer on the tablets.
  • step ii) Lubricate the blend of step i) with magnesium stearate.
  • step iii) Compress the lubricated blend of step ii) into core tablets.
  • step iii) Coat the core tablets of step iii) with the dispersion of step iv) to form a seal- coated core.
  • step viii) Combine the solution of step vi) with the solution of step vii).
  • step x) Add the dispersion of step ix) slowly to the solution of step viii) under stirring, while maintaining the pH at 2.
  • step xi) Coat the seal-coated tablets of step v) with the drug dispersion of step x) to obtain drug-layered tablets.
  • xii) Dissolve polyvinyl alcohol and polyethylene glycol in 0.1 N hydrochloric acid to obtain a clear solution and adjust the pH to 2.
  • step xiv) Add the dispersion of step xiii) slowly to the solution of step xii) under stirring, while maintaining the pH at 2.
  • step xv) Coat the drug-layered tablets of step xi) with the dispersion of step xiv) to obtain an outer coating layer on the tablets.
  • step ii) Lubricate the blend of step i) with magnesium stearate.
  • step iii) Compress the lubricated blend of step ii) into core tablets.
  • step v) Add the dispersion of step v) slowly to the solution of step iv) under stirring, while maintaining the pH at 2.
  • step vii) Coat the core tablets of step iii) with the dispersion of step vi) to form a seal layer over the core.
  • step viii) Add hydroxypropylmethyl cellulose to the drug dispersion of step viii) and maintain the pH at 2.
  • step x) Coat the seal-coated tablets of step vii) with the drug dispersion of step ix) to obtain drug -layered tablets.
  • xii) Disperse talc and titanium dioxide in 0.1 N hydrochloric acid to obtain a uniform dispersion.
  • step xiii) Add the dispersion of step xii) slowly to the solution of step xi) under stirring, while maintaining the pH at 2.
  • step xiv) Coat the drug-layered tablets of step x) with the dispersion of step xiii) to obtain an outer coating layer.
  • step ii) Lubricate the blend of step i) with magnesium stearate.
  • step iii) Compress the lubricated blend of step ii) into core tablets.
  • step iii) Coat the core tablets of step iii) with the dispersion of step iv) to form a seal layer over the core.
  • stepv i) Add hydroxypropylmethyl cellulose to the drug dispersion of stepv i) and maintain the pH at 2.
  • step viii) Coat the seal-coated tablets of step v) with the drug dispersion of step vii) to obtain drug-layered tablets.
  • step x) Coat the drug-layered tablets of step viii) with the dispersion of step ix) to obtain an outer coating layer on the tablets.
  • step ii) Lubricate the blend of step i) with magnesium stearate.
  • step iii) Compress the lubricated blend of step ii) into core tablets.
  • step iv) Combine the solution of step iv) with the solution of step v).
  • step viii) Add the dispersion of step vii) slowly to the solution of step vi) under stirring, while maintaining the pH at 2. ix) Coat the core tablets of step iii) with the drug dispersion of step viii) to obtain drug -layered tablets.
  • step xii) Add the dispersion of step xi) slowly to the solution of step x) under stirring, while maintaining the pH at 2.
  • step xiii) Coat the drug-layered tablets of step ix) with the dispersion of step xii) to obtain an outer coating layer on the tablets.
  • step iii) Add the dispersion of step i) slowly to the solution of step i) under stirring, while maintaining the pH at 2.
  • step vii) Combine the solution of step v) with the solution of step vi).
  • step viii) Add the dispersion of step viii) slowly to the solution of step vii) under stirring, while maintaining the pH at 2.
  • step x) Coat the seal-coated pellets of step iv) with the drug dispersion of step ix) to obtain drug-layered pellets.
  • step xiii) Add the dispersion of step xii) slowly to the solution of step xi) under stirring, while maintaining the pH at 2.
  • step xiv) Coat the pellets of step x) with the dispersion of step xiii) to obtain an outer coating layer.
  • step xv) Fill the coated pellets of step xiv) into hard gelatin capsule shells at a desired fill weight.
  • step ii) Add hydroxypropylmethyl cellulose and sodiumcarboxymethyl cellulose to the mixture of step i) and mix.
  • step iii) Add magnesium stearate to the mixture of step ii).
  • step iv) Compact the blend of step iii) and then pass the compacts through a screen.
  • step v) Granulate colloidal silicon dioxide with purified water and pass through a screen.
  • step v) Mix the granules of step v) with the granules of step iv) to form a blend.
  • step x) Add the dispersion of step ix) slowly to the solution of step viii) under stirring, while maintaining the pH at 2.
  • step xi) Coat the core tablets of step vii) with the dispersion of step x) to form a seal layer over the core.
  • xiii) Dissolve polyvinyl alcohol and polyethylene glycol in 0.1 N hydrochloric acid to obtain a clear solution and adjust the pH to 2.
  • step xiv) Combine the solution of step xii) with the solution of step xiii).
  • step xvi) Add the dispersion of step xv) slowly to the solution of step xiv) under stirring, while maintaining the pH at 2.
  • step xvii) Coat the seal-coated tablets of step xi) with the drug dispersion of step xvi) to obtain drug-layered tablets.
  • xviii) Dissolve hydroxypropylmethyl cellulose in 0.1 N hydrochloric acid to obtain a clear solution.
  • xix) Coat the drug-layered tablets of step xvii) with the dispersion of step xviii) to obtain an outer coating layer on the tablets.
  • step ii) Add hydroxypropylmethyl cellulose and sodiumcarboxymethyl cellulose to the mixture of step i) and mix.
  • step iv) Compact the blend of step iii) and then pass the compacts through a screen.
  • v) Granulate colloidal silicon dioxide with purified water and pass through a screen.
  • step v) Mix the granules of step v) with the granules of step iv) to form a blend.
  • step vii) Coat the core tablets of step vii) with the dispersion of step viii) to form a seal layer over the core.
  • step xii Combine the solution of step x) with the solution of step xi).
  • step xiv) Add the dispersion of step xiii) slowly to the solution of step xii) under stirring, while maintaining the pH at 2.
  • step xv) Coat the seal-coated tablets of step ix) with the drug dispersion of step xiv) to obtain drug -layered tablets.
  • step xviii) Add the dispersion of step xvii) slowly to the solution of step xvi) under
  • step ii) Add hydroxypropylmethyl cellulose and sodiumcarboxymethyl cellulose to the mixture of step i) and mix.
  • step iv) Compact the blend of step iii) and then pass the compacts through a screen.
  • v) Granulate colloidal silicon dioxide with purified water and pass through a screen.
  • step x) Add the dispersion of step ix) slowly to the solution of step viii) under stirring while maintaining the pH at 2.
  • step xi) Coat the core tablets of step vii) with the dispersion of step x) to form a seal layer over the core.
  • step xiii) Add hydroxypropylmethyl cellulose to the drug dispersion of step xii) and maintain the pH at 2.
  • step xiv) Coat the seal-coated tablets of step xi) with the drug dispersion of step xiii) to obtain drug-layered tablets.
  • step xvii) Add the dispersion of step xvi) slowly to the solution of step xv) under stirring, while maintaining the pH at 2.
  • step ii) Add hydroxypropylmethyl cellulose and sodiumcarboxymethyl cellulose to the mixture of step i) and mix.
  • step iv) Compact the blend of step iii) and then pass the compacts through a screen.
  • v) Granulate colloidal silicon dioxide with purified water and pass through a screen.
  • step v) Mix the granules of step v) with the granules of step iv) to form a blend.
  • step vii) Compress the final blend to form core tablets.
  • step vii) Coat the core tablets of step vii) with the dispersion of step viii) to form a seal layer over the core.
  • step xi) Add hydroxypropylmethyl cellulose to the drug dispersion of step x) and maintain the pH at 2.
  • step xii) Coat the seal-coated tablets of step ix) with the dispersion of step xi) to obtain drug -layered tablets.
  • xiii) Disperse hydroxypropylmethyl cellulose in 0.1 N hydrochloric acid to obtain a coating dispersion.
  • step xiv) Coat the drug-layered tablets of step xii) with the dispersion of step xiii) to obtain an outer coating layer on the tablets.
  • Titanium dioxide 2.15
  • step ii) Add hydroxypropylmethyl cellulose and sodiumcarboxymethyl cellulose to the mixture of step i) and mix.
  • step iv) Compact the blend of step iii) and then pass the compacts through a screen.
  • v) Granulate colloidal silicon dioxide with purified water and pass through a screen.
  • step v) Mix the granules of step v) with the granules of step iv) to form a blend.
  • step vii) Compress the final blend to form core tablets.
  • step x) Combine the solution of step viii) with the solution of step ix).
  • step xii) Add the dispersion of step xi) slowly to the solution of step x) under stirring, while maintaining the pH at 2.
  • step xiii) Coat the core tablets of step vii) with the drug dispersion of step xii) to obtain drug -layered tablets.
  • step xvi) Add the dispersion of step xv) slowly to the solution of step xiv) under stirring while maintaining the pH at 2.
  • step vii) Add the dispersion of step vi) slowly to the solution of step v) under stirring, while maintaining the pH at 2.
  • step viii) Coat the extended-release metformin pellets of step iv) with the dispersion of step vii).
  • step xi Combine the solution of step ix) with the solution of step x).
  • step xiii) Add the dispersion of step xii) slowly to the solution of step xi) under stirring, while maintaining the pH at 2.
  • step xvii) Add the dispersion of step xvi) slowly to the solution of step xv) under stirring, while maintaining pH at 2.
  • step xviii) Coat the saxagliptin-coated pellets of step xiii) with the dispersion of step xvii) to obtain an outer coating layer over the pellets.
  • step xix) Fill the pellets of step xviii) into hard gelatin capsule shells at a desired fill weight.

Abstract

La présente invention concerne des compositions pharmaceutiques orales comprenant de la saxagliptine, et des procédés pour leur préparation. L'invention concerne en outre des compositions pharmaceutiques orales comprenant de la saxagliptine combinée avec d'autres agents antidiabétiques.
PCT/IB2014/066137 2013-11-18 2014-11-18 Compositions orales de saxagliptine WO2015071889A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3378/DEL/2013 2013-11-18
IN3378DE2013 2013-11-18

Publications (1)

Publication Number Publication Date
WO2015071889A1 true WO2015071889A1 (fr) 2015-05-21

Family

ID=51999469

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/066137 WO2015071889A1 (fr) 2013-11-18 2014-11-18 Compositions orales de saxagliptine

Country Status (1)

Country Link
WO (1) WO2015071889A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105030724A (zh) * 2015-08-20 2015-11-11 杭州成邦医药科技有限公司 一种抗糖尿病药物的组合物
CN105030719A (zh) * 2015-08-20 2015-11-11 杭州成邦医药科技有限公司 一种含有阿格列汀和吡格列酮的组合物
CN109010298A (zh) * 2018-08-31 2018-12-18 迪沙药业集团有限公司 一种二甲双胍格列吡嗪复方组合物及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US20100074950A1 (en) * 2008-03-14 2010-03-25 Nectid Inc. Anti-diabetic combinations
US7951400B2 (en) 2004-05-28 2011-05-31 Bristol-Myers Squibb Company Coated tablet formulation and method
WO2012031124A2 (fr) * 2010-09-03 2012-03-08 Bristol-Myers Squibb Company Formulations de médicament au moyen d'antioxydants hydrosolubles
WO2013179307A2 (fr) * 2012-05-29 2013-12-05 Mylan Laboratories Limited Compositions pharmaceutiques stabilisées de saxagliptine
WO2014096982A1 (fr) * 2012-12-21 2014-06-26 Wockhardt Limited Compositions pharmaceutiques stables de saxagliptine ou des sels de celle-ci
WO2014122671A2 (fr) * 2013-02-08 2014-08-14 Hetero Research Foundation Compositions orales solides de saxagliptine

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US7951400B2 (en) 2004-05-28 2011-05-31 Bristol-Myers Squibb Company Coated tablet formulation and method
US20100074950A1 (en) * 2008-03-14 2010-03-25 Nectid Inc. Anti-diabetic combinations
WO2012031124A2 (fr) * 2010-09-03 2012-03-08 Bristol-Myers Squibb Company Formulations de médicament au moyen d'antioxydants hydrosolubles
WO2013179307A2 (fr) * 2012-05-29 2013-12-05 Mylan Laboratories Limited Compositions pharmaceutiques stabilisées de saxagliptine
WO2014096982A1 (fr) * 2012-12-21 2014-06-26 Wockhardt Limited Compositions pharmaceutiques stables de saxagliptine ou des sels de celle-ci
WO2014122671A2 (fr) * 2013-02-08 2014-08-14 Hetero Research Foundation Compositions orales solides de saxagliptine

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105030724A (zh) * 2015-08-20 2015-11-11 杭州成邦医药科技有限公司 一种抗糖尿病药物的组合物
CN105030719A (zh) * 2015-08-20 2015-11-11 杭州成邦医药科技有限公司 一种含有阿格列汀和吡格列酮的组合物
CN109010298A (zh) * 2018-08-31 2018-12-18 迪沙药业集团有限公司 一种二甲双胍格列吡嗪复方组合物及其制备方法

Similar Documents

Publication Publication Date Title
US20100323011A1 (en) Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
US7314640B2 (en) Formulation and process for drug loaded cores
EP2178528B1 (fr) Formulations de tartrate de toltérodine stabilisées
KR101401412B1 (ko) 비구아니드 및 티아졸리딘디온 유도체를 포함하는 신규의약학 제형
KR100831771B1 (ko) 서방출과 ｐＨ 의존성 속방출을 나타내는 약제학적 조성물
AU2011271124A1 (en) Controlled release compositions with reduced food effect
CN103285398A (zh) 含有dpp-ⅳ抑制剂和第二种糖尿病药物的复方制剂及其制备方法
EP2468268B1 (fr) Composition de combinaison de vildagliptine et de gliclazide
WO2014080384A1 (fr) Composition pharmaceutique de linagliptine
US20110244050A1 (en) Pulsed-release sildenafil composition and method for preparing said composition
WO2015071889A1 (fr) Compositions orales de saxagliptine
US20120003307A1 (en) Levetiracetam controlled release composition
CN104414992B (zh) 格列吡嗪渗透泵控释片及其制备方法
US20150283248A1 (en) Pharmaceutical compositions of Linagliptin and process for preparation thereof
US20050276848A1 (en) Sustained release neutralized divalproex sodium
WO2013077824A1 (fr) Procédé de fabrication d'une préparation comprenant de la metformine
EP3290023B1 (fr) Composition pharmaceutique à libération prolongée contenant de la rivastigmine
WO2014096982A1 (fr) Compositions pharmaceutiques stables de saxagliptine ou des sels de celle-ci
US20130251793A1 (en) Pharmaceutical composition comprising phentermine and topiramate
WO2015071887A1 (fr) Compositions pharmaceutiques orales de saxagliptine
US8916194B2 (en) Controlled release pharmaceutical compositions of milnacipran
WO2014096983A1 (fr) Compositions pharmaceutiques stables de saxagliptin ou des sels de celui-ci
US20130251795A1 (en) Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent
KR101760278B1 (ko) 에페리손을 유효 성분으로 함유하는 서방성 미립구의 제조방법
WO2019132833A1 (fr) Combinaison à libération modifiée comprenant de la linagliptine et de la metformine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14805358

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14805358

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 26.07.2016)

122 Ep: pct application non-entry in european phase

Ref document number: 14805358

Country of ref document: EP

Kind code of ref document: A1